retatrutide phase 2 trial Great news again!!! A of (Triple–Hormone-Receptor Agonist) for obesity. At 48 wks the median body weight loss was 24.2% and >5%, >10% and >15% had occurred in 100% retatrutide phase 2 trial results
Description
Approval is not expected until mid-2026 or 2027 at the earliest
Intestinal adaptation to cold-induced metabolic demand and feeding requires GLP-1R and GLP-2R signalling
Research Use Only: This product is strictly for laboratory research and is not intended for human or veterinary consumption, therapeutic use, diagnostic use, or clinical application
This extra receptor interaction enhances glucagon production, leading to the breakdown of stored fats and glycogen, thereby increasing basal metabolism for more consistent fat loss
Place it immediately in the refrigerator
Ready to Take the First Step
